Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

目前已有12家中国生物技术初创企业加入拜耳Co.Lab。 中国，2026年3月10日—— 拜耳Co.Lab今日宣布已与艾贝乐医药科技有限公司（以下简称“艾贝乐”）和苏州明澄生物科技有限公司（以下简称“明澄生物”）达成协议。这两家生物技术初创企业将入驻拜耳Co.Lab ...

The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors ...

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...

Cone snails deploy sophisticated venom cocktails to paralyse prey. Anthony King talks to the researchers harnessing these ...

Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...

In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...

Daridorexant is approved and marketed in Japan as QUVIVIQ® under a commercialization agreement between Nxera and Shionogi. QUVIVIQ®, discovered by Idorsia Pharmaceuticals, is marketed by Idorsia in ...

Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...